Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04830501
Other study ID # TT00434CN01
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date July 12, 2021
Est. completion date October 18, 2023

Study information

Verified date November 2023
Source TransThera Sciences (Nanjing), Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase I study of the safety, tolerability, pharmacokinetics profile, and preliminary efficacy of TT-00434 in patients with advanced solid tumors.


Description:

This is a phase I, First-in-Human (FIH), open-label, dose escalation clinical study in patients who have a histological or cytologically confirmed diagnosis of advanced or recurrent tumors that all standard treatments have been used or are not feasible. It aims to determine the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) for study, evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics and the preliminary anti-tumor activity of TT-00434, and explore the relationship between the anti-tumor activity of TT-00434 and the tumor FGFR alterations.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date October 18, 2023
Est. primary completion date October 18, 2023
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - Age = 20 years. - Patients must have a histological or cytologically confirmed diagnosis of advanced or recurrent malignant solid tumors. - Patients have received all currently available standard treatments (unless the therapy is contraindicated, intolerable or unavailable due to any reasons). - Patients must have measurable or evaluable disease (according to RECIST 1.1) - Eastern Cooperative Oncology Group (ECOG) Performance Status = 2 - Must agree to take sufficient contraceptive methods to avoid pregnancy during the study and until at least 6 months after ceasing study treatment - Patients must have fully understood and voluntarily signed informed consent form (ICF) for this study. Exclusion Criteria: - Patients who received other investigational products or devices in other clinical trials within 4 weeks before the first dose. - Patients who received anti-tumor therapy within 4 weeks, or within 5-half-lives (which is longer) before the first dose, including but not limited to chemotherapy, radiotherapy (palliative radiotherapy is completed at least 2 weeks before the first dose can enrol), targeted therapy or immunotherapy. - Patients who have previous toxicity of anti-tumor therapy that has not recovered to Grade 1. (except for = Grade 2 alopecia, chemotherapy-induced peripheral neurotoxicity, and ototoxicity). - Patients who have gastrointestinal disorders that will affect oral administration or the Investigator judges that the absorption of TT-00434 will be interfered. - Patients underwent major surgery (except biopsy) within 4 weeks, or the surgical incision has not completely healed prior to the first dose. - Patients who have active bacterial or fungal infections (CTCAE, Grade = 2) that required systemic treatment within 2 weeks prior to the first dose. - Patients who have active HBV infection (HBV DNA copies = ULN) and/or HCV infection (HCV RNA copies = ULN) - Patients who test positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome. - Has received a live-virus vaccination within 30 days of planned first dose NOTE: Seasonal flu vaccines are permitted. - Known or suspected drug hypersensitivity to any ingredients of TT-00434 tablets. - Female patients in pregnancy or lactation. Male patients or female patients at reproductive ages who are unwilling to receive effective contraceptive measures. - Patients who are judged by the Investigator to be unsuitable for this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TT-00434
Once daily [QD], 28 days/cycle.

Locations

Country Name City State
Taiwan National Cheng Kung University Hospital Tainan
Taiwan Taipei Medical University Hospital Taipei
Taiwan Tri-Service General Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
TransThera Sciences (Nanjing), Inc.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose Limiting Toxicity (DLT) Safety and tolerability At the end of Cycle 1 (each cycle is 28 days)
Primary Incidence of AEs Safety and tolerability up to 30 days from study discontinuation
Secondary Peak Plasma Concentration (Cmax) PK evaluation At the end of Cycle 1 (each cycle is 28 days)
Secondary Area under the plasma concentration versus time curve (AUC) PK evaluation At the end of Cycle 1 (each cycle is 28 days)
Secondary Time of first Occurance of Cmax(tmax) PK evaluation At the end of Cycle 1 (each cycle is 28 days)
Secondary Serum phosphate levels PD biomarker up to 30 days from study discontinuation
Secondary Objective response rate (ORR) Assess anti-tumor activity through study completion, an average of 1 year
Secondary Disease control rate (DCR) Assess anti-tumor activity through study completion, an average of 1 year
Secondary Progression Free Survival (PFS) Assess anti-tumor activity through study completion, an average of 1 year
Secondary Overall Survival (OS) Assess anti-tumor activity through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04972981 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors Phase 1
Completed NCT05086822 - A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors Phase 1
Completed NCT03260322 - A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Phase 1
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT06040541 - Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors Phase 1
Recruiting NCT05862831 - Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT03641794 - Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers Phase 1
Terminated NCT03665129 - IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors Phase 1
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Recruiting NCT05914116 - A Study of DB-1311 in Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT01693562 - A Phase 1/2 Study to Evaluate MEDI4736 Phase 1/Phase 2
Recruiting NCT04387916 - A Study of KC1036 in Patients With Advanced Solid Tumors Phase 1
Completed NCT04095273 - Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Phase 1
Not yet recruiting NCT03692520 - Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors Phase 1
Completed NCT02997176 - An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) Phase 1
Recruiting NCT04446260 - A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT02253992 - An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma Phase 1/Phase 2
Recruiting NCT06076291 - An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT03545971 - A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors. Phase 1